Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: A randomized, open-label, phase 3 trial

Authors

Byoung Chul Cho, Yonsei University
Clifford Robinson, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Thoracic Oncology

Publication Date

12-1-2023

Volume

18

Issue

12

First Page

1731

Last Page

1742

Document Type

Open Access Publication

DOI

10.1016/j.jtho.2023.08.018

Rights and Permissions

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018 Copyright 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Cho, Byoung Chul; Robinson, Clifford; and et al., "Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: A randomized, open-label, phase 3 trial." Journal of Thoracic Oncology. 18, 12. 1731 - 1742. (2023).
https://digitalcommons.wustl.edu/oa_4/3635

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.